Xu XY - Search Results

1

A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease.

Zhang H, Targher G, Byrne CD, Kim SU, Wong VW, Valenti L, Glickman M, Ponce J, Mantzoros CS, Crespo J, Gronbaek H, Yang W, Eslam M, Wong RJ, Machado MV, Yu ML, Ghanem OM, Okanoue T, Liu JF, Lee YH, Xu XY, Pan Q, Sui M, Lonardo A, Yilmaz Y, Zhu LY, Moreno C, Miele L, Lupsor-Platon M, Zhao L, LaMasters TL, Gish RG, Zhang H, Nedelcu M, Chan WK, Xia MF, Bril F, Shi JP, Datz C, Romeo S, Sun J, Liu D, Sookoian S, Mao YM, Méndez-Sánchez N, Wang XY, Pyrsopoulos NT, Fan JG, Fouad Y, Sun DQ, Giannini C, Chai J, Xia ZF, Jun DW, Li GJ, Treeprasertsuk S, Li YX, Cheung TT, Zhang F, Goh GB, Furuhashi M, Seto WK, Huang H, Di Sessa A, Li QH, Cholongitas E, Zhang L, Silveira TR, Sebastiani G, Adams LA, Chen W, Qi X, Rankovic I, De Ledinghen V, Lv WJ, Hamaguchi M, Kassir R, Müller-Wieland D, Romero-Gomez M, Xu Y, Xu YC, Chen SY, Kermansaravi M, Kuchay MS, Lefere S, Parmar C, Lip GYH, Liu CJ, Åberg F, Lau G, George J, Sarin SK, Zhou JY, Zheng MH; MAFLD ICD-11 coding collaborators. Zhang H, et al. Among authors: xu xy, xu yc, xu y. Hepatol Int. 2024 Aug;18(4):1178-1201. doi: 10.1007/s12072-024-10702-5. Epub 2024 Jun 15. Hepatol Int. 2024. PMID: 38878111

2

[Detection of the HBV DNA with Sybr green 1 realtime polymerase chain reaction].

Wang Y, Xu X, He W, Liu Z, Gong W, Wang Q. Wang Y, et al. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2002 Jun;16(2):160-1. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2002. PMID: 12196830 Chinese.

3

Downregulation of CCR5 expression on cells by recombinant adenovirus containing antisense CCR5, a possible measure to prevent HIV-1 from entering target cells.

Li W, Yu M, Bai L, Bu D, Xu X. Li W, et al. J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):516-22. doi: 10.1097/01.qai.0000243102.95640.92. J Acquir Immune Defic Syndr. 2006. PMID: 17019368

4

[High sustained virological response to optimized therapy for refractory chronic hepatitis C treatment-na(i)ve patients: a multicenter randomized study].

Chen X, Shang J, Yang R, Xie Q, Gao Z, Xu X, Dou X, Gong G, Chen G, Li J, Chen H, Zhang D, Feng Y, Niu J, Hou J, You H, Wu Y, Zhao P, Rao H, Wei L. Chen X, et al. Zhonghua Gan Zang Bing Za Zhi. 2015 Jun;23(6):412-7. doi: 10.3760/cma.j.issn.1007-3418.2015.06.004. Zhonghua Gan Zang Bing Za Zhi. 2015. PMID: 26236925 Clinical Trial. Chinese.

5

[The efficacy and prognostic predictors of different treatment courses with pegylated interferon α-2a and ribavirin combination in recurrent chronic hepatitis C patients].

Rao H, Yang R, Shang J, Xu X, Chen X, Dou X, Feng Y, Gao Z, Xie Q, Li J, You H, Chen G, Niu J, Gong G, Hou J, Chen H, Zhang D, Wei L. Rao H, et al. Zhonghua Nei Ke Za Zhi. 2015 Aug;54(8):699-704. Zhonghua Nei Ke Za Zhi. 2015. PMID: 26674626 Clinical Trial. Chinese.

6

Female gender lost protective effect against disease progression in elderly patients with chronic hepatitis B.

You H, Kong Y, Hou J, Wei L, Zhang Y, Niu J, Han T, Ou X, Dou X, Shang J, Tang H, Xie Q, Ding H, Ren H, Xu X, Xie W, Liu X, Xu Y, Li Y, Li J, Chow SC, Zhuang H, Jia J. You H, et al. Sci Rep. 2016 Nov 28;6:37498. doi: 10.1038/srep37498. Sci Rep. 2016. PMID: 27892487 Free PMC article.

7

On-treatment changes of liver stiffness at week 26 could predict 2-year clinical outcomes in HBV-related compensated cirrhosis.

Wu S, Kong Y, Piao H, Jiang W, Xie W, Chen Y, Lu L, Ma A, Xie S, Ding H, Shang J, Zhang X, Feng B, Han T, Xu X, Huo L, Cheng J, Li H, Wu X, Zhou J, Sun Y, Ou X, Zhang H, You H, Jia J. Wu S, et al. Liver Int. 2018 Jun;38(6):1045-1054. doi: 10.1111/liv.13623. Epub 2017 Nov 29. Liver Int. 2018. PMID: 29119705

8

China Registry of Hepatitis B (CR-HepB): Protocol and implementation of a nationwide hospital-based registry of hepatitis B.

Shan S, Wei W, Kong Y, Niu J, Shang J, Xie W, Zhang Y, Ren H, Tang H, Ding H, Nan Y, Dou X, Han T, Xu X, Duan Z, Wei L, Hou J, Zhuang H, You H, Jia J; CR-Hepb Study Group, Beijing, China. Shan S, et al. Scand J Public Health. 2020 Mar;48(2):233-239. doi: 10.1177/1403494818772188. Epub 2018 May 1. Scand J Public Health. 2020. PMID: 29716439

9

Chinese guidelines on the management of ascites and its related complications in cirrhosis.

Chinese Society of Hepatology, Chinese Medical Association; Xu X, Duan Z, Ding H, Li W, Jia J, Wei L, Linghu E, Zhuang H. Chinese Society of Hepatology, Chinese Medical Association, et al. Hepatol Int. 2019 Jan;13(1):1-21. doi: 10.1007/s12072-018-09923-2. Epub 2019 Jan 18. Hepatol Int. 2019. PMID: 30656520

10

Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study.

Wu X, Zhou J, Xie W, Ding H, Ou X, Chen G, Ma A, Xu X, Ma H, Xu Y, Liu X, Meng T, Wang L, Sun Y, Wang B, Kong Y, Ma H, You H, Jia J. Wu X, et al. Infect Drug Resist. 2019 Apr 1;12:745-757. doi: 10.2147/IDR.S185120. eCollection 2019. Infect Drug Resist. 2019. PMID: 31015765 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,498 results

Search Page

Filters